- EPZM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.5 million.
- EPZM has traded 50,382 shares today.
- EPZM is down 4.5% today.
- EPZM was up 12.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in EPZM with the Ticky from Trade-Ideas. See the FREE profile for EPZM NOW at Trade-Ideas More details on EPZM: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. EPZM has a PE ratio of 9.1. Currently there are 2 analysts that rate Epizyme a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Epizyme has been 243,000 shares per day over the past 30 days. Epizyme has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 68.4% year-to-date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Epizyme as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income.